Search results for: Pricing and Reimbursement
Filter search results
James Zackheim – 2022 Prize Finalist
18 January 2023
Dr. James Zackheim, PhD, Vice President – Head of Corporate Strategy and former Head of Patient Access & Pricing in UCB. He is responsible for providing leadership and strategic direction…
Richard Torbett
3 February 2023
Dr Richard Torbett joined ABPI in July 2015 and previously held the role of Executive Director of Economic, Health and Commercial Policy. In this role, Richard was responsible for pricing…
Incentivising New Antibiotics: Designing a Value-Based Delinked Pull Incentive Mechanism
30 March 2023
…and a target product profile (TPP). Following eligibility screening, the company and payer would enter into a contract guaranteeing the company a minimum subscription fee if the criteria and TPP…
OHE’s contribution to health economics
1 May 2023
…respected the OHE’s work and found that it to be of high quality and robust. It’s much better written than typical academic stuff and each brick builds up a wall…
Plan For A New EU Pharmaceutical Legislation: What Will It Mean For Pharmaceutical Innovation?
12 April 2024
…incentives and the addition of targeted incentives is nuanced and careful consideration and research into the intended and unintended consequences is needed. The reform proposals contain other specific measures of…
Green Healthcare: Are We Asking the Right Questions?
11 September 2024
…so that these strategies can be adapted and scaled. Examples include Thailand’s attempts to learn from Singapore’s success in improved access and reduced delays following the adoption of decentralised care….
Drug shortages are on the rise – but what is their impact?
16 September 2024
What are the impacts of a drug shortage? Who is affected? And how significantly? Our latest research report answers these questions and helps policy-makers understand a key trade-off facing health systems…
GLP-1 Receptor Agonists: Shifting Obesity Management
12 May 2025
…side effects like nausea for faster weight loss. These trade-offs aren’t just clinical – they’re personal and behavioural, and they shape treatment adherence and real-world outcomes. Importantly, treatment preferences among…
Common Illness of Our Time: a Study of the Problem of Ischemic Heart Disease
1 July 1966
In England and Wales in 1963, 187,023 deaths were certified as due to diseases of the heart. These included 154,815 deaths due to arteriosclerotic and degenerative heart disease of which…